IRBMMany of our drug hunters have been working at IRBM since before our restructuring into a private company. In fact, in addition to several preclinical candidates currently in clinical trials, they have been responsible for developing or co-developing five marketed drugs thus far, starting with ZOLINZA® in 2006, followed by ISENTRESS® in 2008, NERVENTRA® in 2013, Grazoprevir (one of two active ingredients in ZAPATIER®) in 2016 and ZEJULA® in 2017.